IUDs are usually not recommended for women at high risk for sexually transmitted diseases.
Traditionally, intrauterine devices have not been recommended for women at high risk for sexually transmitted diseases for fear that the devices make them more susceptible to upper genital tract infections. But a retrospective chart analysis of more than 300 women flies in the face of this conventional wisdom.
When researchers presenting at ACOG's 56th Annual Clinical Meeting in New Orleans studied the records of women attending an inner city teaching hospital clinic, 194 of whom were using an IUD and 191 on depot medroxyprogesterone acetate (DMPA), they found those on Depo Provera were significantly more likely to have subsequent STDs or other gynecologic infections. On the other hand, women on the IUDs were more likely to report adverse effects-but less inclined to stop using the device, when compared to the women on DMPA (18.8% vs. 67%, P<.001).
Cropsey KL. Long-term, reversible contraception for high-risk women. Obstet Gynecol. 2008;111(April Suppl):9S.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More